Coronavirus N Protein Modulator for Viral Replication Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies lack effective compounds to treat coronavirus infections, particularly for epidemics caused by coronaviruses like SARS, MERS, and COVID-19, with no FDA-approved drugs or vaccines available to control outbreaks.
Innovation Solution
A compound represented by formula (I) that modulates non-native protein-protein interactions in coronavirus N proteins, specifically stabilizing the dimerization of N-terminal domains to inhibit viral replication and induce abnormal protein oligomerization, thereby reducing viral amounts in host cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral therapies are used, then treatment options are limited, but effectiveness against coronavirus infections is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of antiviral compounds through systematic variation of R1, R2, R3, and R4 substituents in formula (I). This structural parameter optimization enables the compounds to effectively modulate non-native protein-protein interactions in coronavirus N proteins, thereby resolving the contradiction between limited treatment options and insufficient effectiveness by providing new chemical entities with proven antiviral activity.
2Productivity
If no FDA-approved antiviral drugs are available, then development time is extended, but this provides opportunity for novel compound discovery
Solution Approach 1:
The patent embodies preliminary action by pre-optimizing the chemical structure of compounds according to formula (I) with specific substituent patterns before clinical application. The compounds were designed in advance to target coronavirus N protein interactions, and their antiviral efficacy was pre-validated through screening assays. This preliminary structural optimization and validation accelerates drug development by eliminating later-stage optimization steps, directly addressing the time loss issue.
Data Source
AI summary
Provided is a compound of formula (I), where R1 to R4 are as defined herein, and a method for treating a viral infection in a subject in need thereof by administering with the compound. Also provided is a method for screening a compound capable of inhibiting activities of a coronavirus in a host cell, including identifying a compound that modulates a non-native protein-protein interaction in coronaviral nucleocapsid (N) proteins.